NCT06745323
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06745323
Title A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (DeLLphi-309)
Acronym DeLLphi-309
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Amgen
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | TUR | ITA | GRC | GBR | FRA | ESP | DEU | CHE | BRA | BEL | AUS | ARG


No variant requirements are available.